Manifest hyperthyroidism in patient with autoimmune hepatitis (clinical observation)

2021 ◽  
pp. 52-56
Author(s):  
M. A. Livzan ◽  
O. V. Gaus ◽  
D. A. Gavrilenko
Keyword(s):  
Autoimmune Diseases ◽  
Autoimmune Hepatitis ◽  
Clinical Guidelines ◽  
Thyroid Disease ◽  
Liver Diseases ◽  
Sclerosing Cholangitis ◽  
Clinical Observation ◽  
Primary Biliary Cholangitis ◽  
Autoimmune Thyroid Diseases ◽  
Autoimmune Thyroid

Among patients with autoimmune hepatitis concomitant autoimmune diseases occur in 40 % of cases. The most commonly associated autoimmune hepatitis is primary biliary cholangitis, primary sclerosing cholangitis and thyroid disease. With regard to the association of autoimmune liver diseases with each other there is experience in management and this is reflected in the clinical guidelines. Information on the features of comorbidity in autoimmune hepatitis and autoimmune thyroid diseases is very limited. This article presents our own clinical observation of the manifestation of thyrotoxicosis against the background of autoimmune hepatitis.

scholarly journals UPDATE OF THE BRAZILIAN SOCIETY OF HEPATOLOGY RECOMMENDATIONS FOR DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNE DISEASES OF THE LIVER

2019 ◽  
Vol 56 (2) ◽  
pp. 232-241 ◽  
Author(s):  
Cláudia Alves COUTO ◽  
Debora Raquel Benedita TERRABUIO ◽  
Eduardo Luiz Rachid CANÇADO ◽  
Gilda PORTA ◽  
Cynthia LEVY ◽  
...  
Keyword(s):  
Autoimmune Diseases ◽  
Autoimmune Hepatitis ◽  
Primary Sclerosing Cholangitis ◽  
Liver Diseases ◽  
Sclerosing Cholangitis ◽  
Primary Biliary Cholangitis ◽  
Web Based ◽  
Overlap Syndromes ◽  
Brazilian Society ◽  
Consensus Document

ABSTRACT New data concerning the management of autoimmune liver diseases have emerged since the last single-topic meeting sponsored by the Brazilian Society of Hepatology to draw recommendations about the diagnosis and treatment of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), overlap syndromes of AIH, PBC and PSC and specific complications and topics concerning AIH and cholestatic liver diseases. This manuscript updates those previous recommendations according to the best evidence available in the literature up to now. The same panel of experts that took part in the first consensus document reviewed all recommendations, which were subsequently scrutinized by all members of the Brazilian Society of Hepatology using a web-based approach. The new recommendations are presented herein.

Non-viral aspects

2018 ◽  
Vol 1 (2) ◽  
pp. 37-39
Author(s):  
Roongruedee Chaiteerakij
Keyword(s):  
Autoimmune Hepatitis ◽  
Liver Diseases ◽  
Sclerosing Cholangitis ◽  
Promising Result ◽  
Primary Biliary Cholangitis ◽  
Second Line Therapy ◽  
Thai Population ◽  
The Past ◽  
Line Therapy ◽  
New Treatment

Autoimmuneliver diseases, particularly autoimmune hepatitis and primary biliary cholangitis,are not uncommon among the Thai population. This article summarizes main findings of studies of autoimmune liver diseases published during the past year, which included natural history and long-termoutcomes of primary biliary cholangitis treatment, a promising result of the new treatment for primary sclerosing cholangitis and outcomes of a second-line therapy of autoimmune hepatitis.

scholarly journals Autoimmune thyroid disease and other non-endocrine autoimmune diseases

2011 ◽  
Vol 64 (3-4) ◽  
pp. 183-187 ◽  
Author(s):  
Ljiljana Todorovic-Djilas ◽  
Tijana Icin ◽  
Jovanka Novakovic-Paro ◽  
Ivana Bajkin
Keyword(s):  
Autoimmune Disease ◽  
Autoimmune Diseases ◽  
Lupus Erythematosus ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Good Reason ◽  
The Body ◽  
Autoimmune Thyroid Diseases ◽  
Autoimmune Thyroid ◽  
Organ Specific

Introduction, Autoimmune diseases are chronic conditions initiated by the loss of immunological tolerance to self-antigens. They constitute heterogeneous group of disorders, in which multiple alterations in the immune system result in a spectrum of syndromes that either target specific organs or affect the body systematically. Recent epidemiological studies have shown a possible shift of one autoimmune disease to another or the fact that more than one autoimmune disease may coexist in a single patient or in the same family. Numerous autoimmune diseases have been shown to coexist frequently with thyroid autoimmune diseases. Autoimmune thyroid disease and other organ specific non-endocrine autoimmune diseases. This part of the study reviews the prevalence of autoimmune thyroid disease coexisting with: pernicious anaemia, vitiligo, celiac disease, autoimmune liver disease, miastenia gravis, alopecia areata and sclerosis multiplex, and several recommendations for screening have been given. Autoimmune thyroid disease and other organ non-specific non-endocrine autoimmune diseases. Special attention is given to the correlation between autoimmune thyroid disease and rheumatoid arthritis, systemic lupus erythematosus, syndrome Sj?gren, systemic sclerosis and mixed connective tissue disease. Conclusions. Screening for autoimmune thyroid diseases should be recommended in everyday clinical practice, in patients with primary organ-specific or organ non-specific autoimmune disease. Other?wise, in patients with primary thyroid autoimmune disease, there is no good reason of seeking for all other autoimmune diseases, although these patients have a greater risk of developing other autoimmune disease. Economic aspects of medicine require further analyzing of these data, from cost/benefit point of view to justified either mandatory screening or medical practitioner judgment.

scholarly journals Extrahepatic Autoimmune Diseases in Patients with Autoimmune Liver Diseases: A Phenomenon Neglected by Gastroenterologists

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Liping Guo ◽  
Lu Zhou ◽  
Na Zhang ◽  
Baoru Deng ◽  
Bangmao Wang
Keyword(s):  
Autoimmune Diseases ◽  
Thyroid Disease ◽  
Genetic Background ◽  
Liver Diseases ◽  
Autoimmune Thyroid Disease ◽  
Clinical Impact ◽  
Current View ◽  
Autoimmune Thyroid ◽  
Autoimmune Liver Diseases ◽  
Prompt Diagnosis

Autoimmune liver diseases (AILDs) often coexist with other extrahepatic autoimmune diseases (EHAIDs). The spectrum of EHAIDs in patients with AILDs is similar, whereas the incidence is different. Notably, autoimmune thyroid disease and Sjogren’s syndrome are the most common EHAIDs. Associated extrahepatic diseases may predate the appearance of AILDs or coincide with their onset. More frequently, they may appear during the course and even occur years after the diagnosis of AILDs. Importantly, associated EHAIDs may influence the natural course and prognosis of AILDs. To date, a definite pathophysiological pathway which contributes to the coexistence of AILDs and EHAIDs is still lacking. The current view of autoimmunity clustering involves a common susceptibility genetic background which applies to related pathologies. Herein, we review the current published researches regarding EHAIDs in patients with AILDs, particularly in relation to their clinical impact and pathophysiology. In managing patients with AILDs, gastroenterologists should be aware of the possibly associated EHAIDs to ensure a prompt diagnosis and better outcome.

scholarly journals Immunological relationship between autoimmune liver disease and autoimmune thyroid disease:a cross-sectional study

2019 ◽  
Author(s):  
Qingmin Zeng ◽  
Min Gao ◽  
Chunyan Wang ◽  
Xu Han ◽  
Chen Chen ◽  
...  
Keyword(s):  
Liver Disease ◽  
Autoimmune Hepatitis ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Autoimmune Liver Disease ◽  
Primary Biliary Cholangitis ◽  
Thyroid Peroxidase ◽  
Cross Sectional ◽  
Autoimmune Thyroid ◽  
Immunological Relationship

Abstract Background: High prevalence of autoimmune thyroid disease (AITD) in patients with autoimmune liver disease (AILD) has been observed. Data on the clinical relationship between AILD and AILD remain scanty. We aimed to evaluate the immunological relationship between AILD and AITD. Results: 324 patients with AILD were enrolled, 113 out of 324 patients were concurrent AITD (34.9%). Patients with autoimmune hepatitis (AIH) were more likely to develop AITD (45.8%), followed by autoimmune hepatitis-primary biliary cholangitis overlap syndrome (AIH-PBC OS) (39.5%) and PBC (22.6%). AILD patients with concurrent AITD showed higher levels of IgG (21.5 g/L vs 16.3 g/L, P<0.0001) and gamma globulin (γ-globulin)(27.1% vs 21.9%, P<0.0001), and IgG were positively correlated with thyroid antibodies [thymoglobulinantibody (TGAb), thyroid peroxidase antibody (TPOAb)] (r=0.396, 0.322; P<0.0001, P=0.002, respectively). The frequency of TPOAb positivity was highest in PBC patients with concurrent AITD (83.9%). The AIH concomitant with AITD had a higher nuclear homogenizing antinuclear antibody (ANA) positivity compared with the AIH alone (P=0.019). PBC patients with concurrent AITD were significantly older than the PBC patients without AITD (P=0.0004). Thyroid dysfunction in AILD patients with concurrent AITD was principally characterized by Hashimoto's thyroiditis (65.5%) and diffuse lesions were mainly indicated in thyroid ultrasound (53.1%). Conclusions: The high incidence of AILD concomitant with AITD, as well as the higher levels of serum IgG and γ-globulin, and the strong correlation between thyroid antibody and IgG, suggesting that we should strengthen the screening of autoimmune thyroid disease when diagnosing and treating autoimmune liver disease.

scholarly journals Autoimmune thyroid disease and associated diseases

2005 ◽  
Vol 133 (Suppl. 1) ◽  
pp. 84-87 ◽  
Author(s):  
Mirjana Lapcevic
Keyword(s):  
Autoimmune Diseases ◽  
Lupus Erythematosus ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Multidisciplinary Treatment ◽  
Care Physician ◽  
Medical Attention ◽  
Morbus Addison ◽  
Autoimmune Thyroid ◽  
Associated Diseases

Autoimmune thyroid disease (ATD) is a multifactorial, genetic disease. It is the sequelae of the impaired immunoregulation, tolerance and poor recognition of one?s own proteins, oligopolysaccharides and polypeptides, due to development of somatic lymphocyte mutations. It is manifested by different clinical and morphological entities, inter-related by etiopathogenetic association, i.e., all of them are caused by disorder of immune system regulation. Chronic autoimmune thyroidism (Thyreoiditis lymphocytaria Hashimoto, HT), as well as immunogenic hyperthyroidism (Morbus Graves Basedow, MGB) are frequently associated with autoimmune diseases of other organs, such as: chronic insufficiency of salivary glands (Sy Sj?gren), autoimmune hemolytic anemia, megalocytic pernicious anemia, thrombocytopenia, Rheumatoid arthritis, Diabetes mellitus (more often type 2, but also type 1), Morbus Addison, Coeliakia, and other autoimmune diseases such as systemic diseases of connecting tissue (Lupus erythematosus-SLE, Sclerodermia, Vasculitis superficialis). The incidence of autoimmune diseases has been at increase in all age groups of our population. The prevalence of organ-specific and organ-nonspecific antibodies increases with the age. Antigenicity of thyroid epithelial cell may be triggered by different chemical and biological agents (repeated viral infections), repeated stress, and in individuals with genetic propensity. Unrecognized ATD progressively leads to hypothyroidism with hyperlipidemia, blood vessel changes, osteoporosis, deformities, invalidity which substantially reduces the quality of life of patient and requires medical attention and expensive treatment on what account it is medically and socio-economically significant. Multiple diagnostic procedures contribute to faster recognition of this condition. The goal of the primary health care physician (given that preclinical phase of ATD and other associated diseases have different duration) and other specialists is to recognize ATD and, by early diagnosis and multidisciplinary treatment, to take secondary preventive measures of manifestation of above-mentioned associated autoimmune diseases, and in that way, to avoid the development of comorbidity and complications. It is particularly supported by medical doctrine based on evidence of application of corticosteroids, cytostatics, thyro-suppressive and substitution therapy, antilipemics, bisphosphonates and other drugs, significant for autoimmune diseases.

scholarly journals The role of selenium in the pathogenesis of thyroid disease

2019 ◽  
Vol 14 (4) ◽  
pp. 192-205 ◽  
Author(s):  
Ekaterina A. Troshina ◽  
Evgeniya S. Senyushkina ◽  
Maria A. Terekhova
Keyword(s):  
Immune Response ◽  
Thyroid Disease ◽  
Animal Experiments ◽  
Optimal Level ◽  
Thyroid Diseases ◽  
Autoimmune Thyroid Diseases ◽  
Autoimmune Thyroid ◽  
Increased Risk ◽  
Combined Deficiency

The past few years have been actively discussing the role of individual macro- and micronutrients as factors regulating the functional activity of organs and systems and reducing the risk of developing a number of diseases, including thyroid diseases. Selenium is one of the most important and intensively studied at present microelements. According to several studies, its low plasma level is associated with an increased risk of developing autoimmune thyroid diseases. In animal experiments, it was shown that a combined deficiency of selenium and iodine leads to more pronounced hypothyroidism than iodine deficiency alone. Some authors believe that cretinism in the newborn is a consequence of the combined deficiency of these two elements in the mother. It is also important that the optimal level of selenium is necessary both to initiate an immune response and to regulate an excessive immune response, as well as chronic inflammation. The review article discusses the relationship between selenium and thyroid pathology, discusses the role of selenium in the physiology of the thyroid gland and in the development of autoimmune diseases. The biochemical aspects of the pathogenesis of thyroid disease are presented.

Vitamin D and autoimmune thyroid diseases (part 1)

2021 ◽  
pp. 6-15
Author(s):  
N. V. Volkova ◽  
A. V. Solntseva
Keyword(s):  
Vitamin D ◽  
Autoimmune Diseases ◽  
Immune Cells ◽  
Therapeutic Potential ◽  
Immunosuppressive Agents ◽  
Thyroid Tissue ◽  
Thyroid Diseases ◽  
Autoimmune Thyroid Diseases ◽  
Autoimmune Thyroid ◽  
Autoimmune Pathology

Autoimmune thyroiditis (AIT) and Graves’ disease (GD) are common autoimmune diseases, and their prevalence assessed as 5 % of general population. Currently, selective immunosuppressive agents for pathogenetic treatment of autoimmune pathology are being developed. Vitamin D with the known anti­inflammatory and immunoregulatory properties, is also of great interest. The first part of the article reviews the roles of various immune cells in the pathogenesis of autoimmune thyroid diseases, which is necessary to reveal the therapeutic potential of calcitriol in these disorders. Classically, AIT was considered to be mediated by T­helpers type 1 (Th1), and GD — by T­helpers type 2 (Th2). This misunderstanding was based on the idea that humoral immunity is controlled by Th2 cytokines, and cellular immunity — by Th1. In the past decades, the role of new subsets of immune cells in the pathogenesis of autoimmune thyroid diseases is being studied, displacing the traditional paradigm of Th1/Th2 dichotomy. It has been established that T­helpers type 17 (Th17) play an important role in the development of various inflammatory and autoimmune diseases, previously classified as Th1­dependent pathologies. The involvement of T­ and B­regulatory lymphocytes in the autoimmune process is also of particular interest. It was found that these cells accumulate in inflamed thyroid tissue in patients with thyroid pathology, but they are unable to suppress the immune response effectively. Further research will help to find out which immune cells can become targets for vitamin D agonists in the complex treatment of autoimmune diseases.

Sign in / Sign up

Export Citation Format

Share Document